24 Hour Crisis Hotline
800-336-0341
 
Know Your Rights
- Customer Service
- Recipient Rights
Medications
Resources
Basic InformationMore InformationLatest News
Health Tip: Packing Prescriptions for TravelDrug Errors Peak in July When New Docs StartFDA Warns Consumers Against Swallowing Topical BenadrylStudy Shows Some Anti-Seizure Meds Raise Suicide RiskPrescriptions Translated to Spanish Could Be Hazardous to HealthTougher-to-Abuse Form of OxyContin ApprovedVaccines-By-Patch Good News for Needle-PhobicRifaximin Maintains Remission in Patients With Liver DiseaseMenstrual Cramps May Be Helped by New DrugNew Inhaled Insulin Shows Promise for DiabetesPlavix Can Help Cut Death Risk in Certain Heart PatientsFDA Asks Docs to Suspend Using Glaxo Rotavirus VaccineFDA Says High-Dose Simvastatin Ups Myopathy RiskHigh-Dose Zocor Boosts Muscle Injury Risk: FDAAvandia Researchers' Financial Ties QuestionedCarbaglu Approved for Rare Genetic DisorderACC: New Dual-Acting Drug Lowers Blood PressureNewer Blood Thinner Beats Plavix for Bypass PatientsArthritis Drug May Fight Diabetes, Too2 Drugs Fail to Prevent Diabetes in the OverweightFDA Adds Boxed Warning to Clopidogrel LabelThiazolidinediones Not Linked to Diabetic Macular EdemaYoung Kids to Benefit From Broader Pneumococcal VaccineBleeding Alert Sounded for Stroke DrugsLink Between Diabetes and Neuroleptic Drugs OutlinedResistance Likely to Develop With New Hepatitis C DrugsLasofoxifene Examined in Postmenopausal WomenSuccessor to Combination Pneumococcal Vaccine ApprovedMenveo Vaccine Approved for Bacterial MeningitisFDA: No Decision on Whether to Pull Diabetes Drug Avandia Off the MarketRituxan Approved for Chronic Lymphocytic LeukemiaNew Technology Could Widen Reach of VaccinesFDA Issues Warning on Key Asthma DrugsFDA Issues Maalox Total Relief WarningIbuprofen May Help Stave Off Parkinson'sFDA Tightens Controls on Anemia DrugsAdded Drug Aids MS Treatment'Fishy Smell' May Keep Patients From Diabetes DrugBotox May Prevent Some MigrainesAnother Study Refutes Vaccination-Autism LinkCrestor Approval ExpandedParoxetine May Compromise the Efficacy of TamoxifenNeedle Length May Affect Vaccination Results in ObeseDrug May Ease Cognitive Effects of Huntington'sGlaucoma Drugs May Play Role in Longer LifeH1N1 Vaccination Still Highly RecommendedThe Lancet Retracts Study Linking MMR Vaccine, AutismXiaflex Approved for Rare Hand ConditionAntidepressants After Stroke May Boost Mental AbilityFDA Revises Label for the HIV Drug Didanosine
Questions and AnswersLinksBook Reviews
Related Topics

Anxiety Disorders
Depression: Major Depression & Unipolar Varieties
Medical Disorders
Mental Disorders

Ibuprofen May Help Stave Off Parkinson's

HealthDay News
by By Ellin HolohanHealthDay Reporter
Updated: Feb 17th 2010

 

new article illustration

WEDNESDAY, Feb. 17 (HealthDay News) -- Regular use of ibuprofen, a common anti-inflammatory drug, significantly lowers the risk for developing Parkinson's disease, Harvard researchers report.

People who took three or more tablets a week showed a 40 percent lower risk than those who didn't take the common pain reliever, their study found.

Study author Dr. Xiang Gao, an instructor and epidemiologist at Harvard Medical School and Brigham and Women's Hospital in Boston, said the findings are important for anyone at increased risk for Parkinson's because most people with the disease eventually become severely disabled.

"There is thus a need for better preventive interventions," Gao said. "In this context, our findings regarding the potential neuroprotective effect of ibuprofen, one of the most commonly used analgesics, on Parkinson's disease may have important public health and clinical implications."

Parkinson's is a disease that affects nerve cells in the brain that control the movement of muscles. It affects an estimated 1 million people in the United States, men far more often than women. The exact cause is unknown, but experts believe it's a combination of genetic and environmental factors.

Gao said that though the drug levodopa is the current standard treatment for Parkinson's, much more is needed. He is scheduled to present the findings in Toronto at the annual meeting of the American Academy of Neurology in April.

The findings came from an analysis of data on 136,474 people who did not have Parkinson's at the start of the study. In a six-year span, 293 were diagnosed with the disease. Those who took the largest doses of ibuprofen were less likely to have developed Parkinson's than were those who took smaller amounts of the drug, the study found.

No other pain reliever was found to lower the risk for Parkinson's.

Dr. Michele Tagliati, an associate professor of neurology and director of the Parkinson's Disease Center at the Mount Sinai School of Medicine in New York City, described the results as somewhat surprising and said they emphasized the need for further study.

"It's intriguing [that the finding applied to] just ibuprofen and not aspirin or acetaminophen or other commonly prescribed medications for inflammation because it implies something more specific to ibuprofen that should be investigated," Tagliati said. "So it narrows the focus to a subgroup of [anti-inflammatory drugs]."

Tagliati called the study "eye-opening." Parkinson's is not considered an inflammatory disease, he said, adding: "We might be missing something. There is more work to be done."

But in the meantime, Tagliati said, he would "definitely discuss ibuprofen use" with his patients because, if it works to protect against the disease, it could very well benefit those who already have it.

He cautioned that persistent use of ibuprofen can lead to gastritis, or inflammation of the stomach lining, but said that, in comparison, "there is very little to lose when measuring its side effects against the effects of Parkinson's," which can include loss of balance, stiffness, hallucinations and dementia.

More information

The National Parkinson's Foundation has more on Parkinson's disease.




Contact Riverwood Center 

By Mail
Riverwood Center
P.O. Box 547
Benton Harbor, MI 49023

By Email
info@riverwoodcenter.org

By Phone
Main: 269-925-0585
Niles: 269-684-4270

By Fax
269-927-6063


powered by centersite dot net